新型组织生物瓣膜主动脉瓣置换术后七年结局
该国际器械豁免试验纳入2013年1月至2016年3月间689例接受新型组织生物瓣主动脉瓣置换的患者,平均年龄66.9±11.6岁,随访5.3±2.2年。7年全因死亡免除率为85.4%,结构性瓣膜衰败免除率为99.3%,7年有效瓣口面积1.82±0.57 cm²、平均压差9.4±4.5 mm Hg。
要点
- 7年全因死亡免除率为85.4%,结构性瓣膜衰败免除率为99.3%。
- 7年有效瓣口面积1.82±0.57 cm²,平均压差9.4±4.5 mm Hg。
- 7年瓣周反流以无(96.8%)或微量(2.5%)为主。
核心结论
- 该新型组织瓣膜在7年随访中表现出优异结局,为未来外科和经导管瓣膜假体树立了基准。
研究设计与样本
- 国际器械豁免试验,689例患者接受新型组织生物瓣主动脉瓣置换,每年随访,5年时部分患者重新知情同意延长至10年随访。
- 安全终点由独立临床事件委员会裁定,超声心动图测量由专门核心实验室裁定。
主要发现
- 随访时间5.3±2.2年(3665.6患者年),194例和195例分别完成6年和7年随访。
- 1年、5年和7年全因死亡免除率分别为97.7%、89.4%和85.4%。
- 7年结构性瓣膜衰败免除率为99.3%。
- 7年有效瓣口面积为1.82±0.57 cm²(n=153),平均压差为9.4±4.5 mm Hg(n=157)。
- 7年瓣周反流以无为主(96.8%[152/157])或微量/痕迹(2.5%[4/157]),跨瓣反流以无(84.7%[133/157])或微量/痕迹(11.5%[18/157])为主。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: As bioprosthetic aortic valve replacement (AVR) extends to younger cohorts, tissue durability is of paramount importance. We report 7-year outcomes from an AVR bioprosthesis utilizing novel tissue. METHODS: This was an international investigational device exemption trial for novel AVR with annual follow-up and a subset re-consented at 5 years for extended 10-year follow-up. Safety end points and echocardiographic measurements were adjudicated by an independent clinical events committee and by a dedicated core laboratory, respectively. RESULTS: Between January 2013 and March 2016, 689 patients underwent AVR with the study valve. Mean age was 66.9 ± 11.6 years, Society of Thoracic Surgeons risk score was 2.0% ± 1.8%, and 74.3% of patients were New York Heart Association functional class II and III. Five-year follow-up was completed by 512 patients, and 225 re-consented for extended follow-up. Follow-up duration was 5.3 ± 2.2 years (3665.6 patient-years), and 194 and 195 patients completed 6- and 7-year follow-ups, respectively. One-, 5-, and 7-year freedom from all-cause mortality was 97.7%, 89.4%, and 85.4%, respectively. Freedom from structural valve deterioration at 7 years was 99.3%. At 7 years, effective orifice area and mean gradients were 1.82 ± 0.57 cm2 (n = 153), and 9.4 ± 4.5 mm Hg (n = 157), respectively. At 7 years, predominantly none (96.8% [152 out of 157]) or trivial/trace (2.5% [4 out of 157]) paravalvular regurgitation and none (84.7% [133 out of 157]) or trivial/trace (11.5% [18 out of 157]) transvalvular regurgitation were observed. CONCLUSIONS: We report the longest surgical AVR follow-up with novel tissue in an investigational device exemption trial utilizing an independent clinical events committee and an echocardiography core laboratory. This tissue demonstrates excellent outcomes through 7 years and is the benchmark for future surgical and transcatheter prostheses.
引用
- Beaver T, Bavaria JE, Griffith B, et al. Seven-year outcomes following aortic valve replacement with a novel tissue bioprosthesis. J Thorac Cardiovasc Surg. 2023. PMID: 37778503. doi:10.1016/j.jtcvs.2023.09.047
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。